Galena Biopharma Reports Positive GALE-301 Phase 2a Trial Data - Quick Facts

(RTTNews) - Galena Biopharma, Inc. (GALE) announced that data from the GALE-301 Phase 2a portion of the Phase 1/2a clinical trial was presented at the European Cancer Congress 2015 in Vienna, Austria. GALE-301 is Galena's cancer immunotherapy that consists of a peptide derived from Folate Binding Protein.

"This one-year data from our GALE-301 trial is extremely encouraging as it has established the optimal dose while demonstrating clear signs of improvement in the disease free status of women with endometrial and ovarian cancer in the 1000 mcg cohort," said Mark Schwartz, President and CEO.

GALE-301 is combined with the immune adjuvant, granulocyte macrophage-colony stimulating factor and administered via intradermal injection for the prevention of recurrence in ovarian and endometrial cancers.